Anti-Diabetes Drugs - NAFTA | Statista Market Forecast

The Anti-Diabetes Drugs market in NAFTA is predicted to witness a substantial growth in revenue, with a projected value of US$40.06bn by 2024.
This market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 6.88%, leading to a market volume of US$55.87bn by 2029.
Among the NAFTA countries, United States is anticipated to generate the highest revenue, reaching US$37.84bn in 2024.
The demand for anti-diabetes drugs is increasing in the NAFTA region due to the rising prevalence of diabetes among the population.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in NAFTA has been experiencing significant growth over the past few years due to various reasons.

Customer preferences: The customers in NAFTA have been showing a higher preference for anti-diabetes drugs due to the increasing prevalence of diabetes in the region. The aging population and sedentary lifestyles have been contributing factors to the rising number of diabetic patients. Customers have also been seeking more convenient and easy-to-use drugs that can help them manage their condition effectively.

Trends in the market: The United States has been the largest market for anti-diabetes drugs in NAFTA, with a large number of diabetic patients and a high demand for innovative drugs. The market has been witnessing a shift towards newer drugs that offer better efficacy and fewer side effects. There has also been an increasing trend towards personalized medicine, with drugs being tailored to individual patient needs.In Canada, the market has been growing steadily, with a focus on the development of new drugs and therapies. The government has been taking steps to improve access to diabetes care, including the provision of free diabetes medications for low-income individuals. The market has also been witnessing a trend towards the adoption of digital health technologies, such as telemedicine and mobile health apps.In Mexico, the market has been growing rapidly due to the increasing prevalence of diabetes and the rising demand for effective treatments. The market has been witnessing a trend towards the use of generic drugs, which are more affordable and accessible to a larger population. There has also been a growing focus on the development of innovative drugs and therapies, with several local players entering the market.

Local special circumstances: The market in NAFTA has been affected by various local circumstances, such as regulatory policies, healthcare infrastructure, and cultural factors. In the US, the market has been influenced by the high cost of drugs and the complex regulatory environment. In Canada, the market has been affected by the government's role in healthcare and the need to balance access with affordability. In Mexico, the market has been impacted by the lack of adequate healthcare infrastructure and the need to improve access to care in rural areas.

Underlying macroeconomic factors: The growth of the Anti-Diabetes Drugs market in NAFTA has been driven by various underlying macroeconomic factors, such as population demographics, healthcare spending, and technological advancements. The aging population and rising healthcare costs have been contributing to the increasing demand for anti-diabetes drugs. The development of new drugs and therapies, as well as the adoption of digital health technologies, has been driving innovation in the market. The market has also been influenced by global macroeconomic factors, such as trade policies and economic growth.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.